Citation | Devasthale, P; Wang, Y; Wang, W; Fevig, J; Feng, J; Wang, A; Harrity, T; Egan, D; Morgan, N; Cap, M; Fura, A; Klei, HE; Kish, K; Weigelt, C; Sun, L; Levesque, P; Moulin, F; Li, YX; Zahler, R; Kirby, MS; Hamann, LG Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778). J Med Chem56:7343-57 (2013) [PubMed] Article |
---|
SMILES | COc1ccc(cc1)-n1cc2[nH]c(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2c1=O |(14.54,-2.86,;15.32,-4.18,;16.86,-4.18,;17.62,-2.84,;19.16,-2.83,;19.93,-4.16,;19.18,-5.5,;17.64,-5.51,;21.47,-4.15,;22.38,-2.89,;23.85,-3.36,;25.18,-2.6,;26.52,-3.36,;27.85,-2.59,;26.52,-4.91,;27.86,-5.68,;29.19,-4.9,;25.19,-5.68,;25.18,-7.22,;23.85,-7.98,;23.84,-9.52,;25.17,-10.3,;25.17,-11.84,;26.51,-9.52,;26.51,-7.99,;27.85,-7.22,;23.86,-4.91,;22.39,-5.4,;21.92,-6.87,)| |